Pulmonary arterial hypertension is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in increased pulmonary vascular resistance and ultimately leading to right heart failure.
It is a part of the spectrum of pulmonary hypertension, which is hemodynamic and pathophysiological condition defined as an increase in mean pulmonary arterial pressure ≥25 mmHg at rest.
Typical symptoms include progressive dyspnea on exertion, palpitations, fatigue, weakness, angina, syncope and abdominal distention.
Inhaled treprostinil significantly improves exercise capacity in terms of 6-minute walking distance (6MWD) over 16 weeks compared with placebo in patients with pulmonary hypertension associated with interstitial lung disease (ILD), according to the INCREASE trial presented at ATS 2020.
Adding selexipag to the double combination therapy of macitentan and tadalafil (triple combination) improved multiple outcomes in patients newly diagnosed with pulmonary arterial hypertension (PAH), results of the phase IIIb TRITON* trial showed.
Use of the oral phosphodiesterase-5 inhibitor udenafil in the treatment of patients with pulmonary arterial hypertension is safe and leads to a significant increase in exercise capacity, according to the results of a phase IIB trial.
The reduced mortality/morbidity benefit previously demonstrated with selexipag in patients with pulmonary arterial hypertension (PAH) may be more pronounced when treatment is initiated soon after diagnosis, according to results of a post hoc analysis of the GRIPHON* study presented as a poster at ATS 2019.
Patients with chronic thromboembolic pulmonary hypertension (CTEPH) may experience improvements in exercise capacity and other outcomes when treated with a continuous, subcutaneous, high dose of treprostinil, according to the phase III CTREPH* trial.
Pulmonary arterial hypertension (PAH) may be the first manifestation of primary Sjögren's syndrome (pSS) in patients with Raynaud’s phenomenon, high-titre rheumatoid factor, hepatic injury or pericardial effusion, according to a recent study.
Endorsement of unproven COVID-19 treatments by high-profile public figures led to a drastic increase in the search and purchase of said treatments in the US, according to a research letter published in JAMA.
Patients with coronavirus disease 2019 (COVID-19) have significant gut dysbiosis that persists even after viral clearance and resolution of respiratory symptoms, according to a metagenomic study by the Chinese University of Hong Kong (CUHK). These findings have led to the development of a probiotic supplement expected to be available in a few months.